Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis

References

• National Psoriasis FoundationModerate to severe psoriasis and psoriatic arthritis: biologics Available from: http://www.psoriasis.org/about-psoriasis/treatments/biologicsAccessed March 27, 2015
   Google Scholar
• RachakondaTDSchuppCWArmstrongAWPsoriasis prevalence among adults in the United StatesJ Am Acad Dermatol201470351251624388724
   PubMed Web of Science ®Google Scholar
• National Institute of Arthritis and Musculoskeletal and Skin DiseasesQuestions and answers about psoriasis102013 Available from: http://www.niams.nih.gov/Health_Info/Psoriasis/Accessed March 27, 2015
   Google Scholar
• NavariniAALaffitteEConradCEstimation of cost-of-illness in patients with psoriasis in SwitzerlandSwiss Med Wkly2010140859119924580
   PubMed Web of Science ®Google Scholar
• DriessenRJBisschopsLAAdangEMEversAWVan De KerkhofPCDe JongEMThe economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologicsBr J Dermatol20101621324132920163420
   PubMed Web of Science ®Google Scholar
• GhatnekarOLjungbergWirestrandLESvenssonACosts and quality of life for psoriatic patients at different degrees of severity in southern Sweden – a cross-sectional studyEur J Dermatol20122223824522361745
   PubMed Web of Science ®Google Scholar
• EkelundMMallbrisLQvitzauSStenbergBA higher score on the Dermatology Life Quality Index, being on systemic treatment and having a diagnosis of psoriatic arthritis is associated with increased costs in patients with plaque psoriasisActa Derm Venereol20139368468823603935
   PubMed Web of Science ®Google Scholar
• LevyARDavieAMBrazierNCEconomic burden of moderate to severe plaque psoriasis in CanadaInt J Dermatol2012511432144023171010
   PubMed Web of Science ®Google Scholar
• Lewis-BeckCAbouzaidSXieLBaserOKimEAnalysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modelingPatient Pref Adherence20137199205
   PubMed Web of Science ®Google Scholar
• FeldmanSRMalakoutiMKooJYSocial impact of the burden of psoriasis: effects on patients and practiceDermatol Online2014208 pii:13030/qt48r4w8h2
   Google Scholar
• SandovalLFFeldmanSRBiologics in practice: adherence to biologic therapy in psoriasisDermatologist20132123034
   Google Scholar
• FinlayAYOrtonneJPPatient satisfaction with psoriasis therapies: an update and introduction to biologic therapyJ Cutan Med Surg20048531032015868312
   PubMed Web of Science ®Google Scholar
• NorlinJMSteen CarlssonKPerssonUSchmitt-EgenolfMResource use in patients with psoriasis after the introduction of biologics in SwedenActa Derm Venereol201595215616124819980
   PubMed Web of Science ®Google Scholar
• UhlenhakeEEMehreganDAUstekinumab: differential use in psoriasisClin Cosmet Investig Dermatol201149399
   Google Scholar
• ArmstrongAWRobertsonADWuJLebwohlMGUndertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011JAMA Dermatol2013149101180118523945732
   PubMed Web of Science ®Google Scholar
• SchaarschmidtM-LUmarNSchmiderAPatient preferences for psoriasis treatments: impact of treatment experienceJ Eur Acad Dermatol Venereol20121471112851294
   Google Scholar
• de KorteJSprangersMAMombersFMBosJDQuality of life in patients with psoriasis: a systematic literature reviewJ Investig Dermatol Symp Proc20049140147
   PubMed Web of Science ®Google Scholar
• BarbosaCDBalpMMKulichKGermainNRofailDA literature review to explore the link between treatment satisfaction and adherence, compliance, and persistencePatient Prefer Adherence20126394822272068
   PubMed Web of Science ®Google Scholar
• Callis DuffinKYeungHTakeshitaJPatient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practiceBr J Dermatol2014170367268024266717
   PubMed Web of Science ®Google Scholar
• PuigLTreatment of moderate to severe plaque psoriasis with biologics: analysis of the additional cost of temporary dose escalation vs switch to another biologic after failure of maintenance therapyActas Dermosifiliogr2014105440141224444743
   PubMedGoogle Scholar
• Degli EspostiLSangiorgiDPerroneVAdherence and resource use among patients treated with biologic drugs: findings from BEETLE studyClinicoecon Outcomes Res2014640140725258545
   PubMedGoogle Scholar
• AyalaFLambertJon Behalf of the TANGO Study GroupEfficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis: a multicenter, open-label trial (TANGO)J Dermatolog Treat2014181825231176
   PubMed Web of Science ®Google Scholar
• UmarNYamamotoSLoerbroksATerrisDElicitation and use of patients’ preferences in the treatment of psoriasis: a systematic reviewActa Derm Venereol201292434134622278662
   PubMed Web of Science ®Google Scholar
• CarterCSchenkelBFreedmanDAn approach to patient-centered care for patients with psoriatic arthritisJ Am Acad Dermatol2013684AB192
   Web of Science ®Google Scholar
• United States Census BureauUS Department of Commerce, Economics, and Statistics Administration. Census Regions and Divisions of the United States Available from: http://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdfAccessed March 27, 2015
   Google Scholar
• Centers for Disease Control and PreventionInternational Classification of Diseases, Ninth Revision, Clinical Modification. Last revision 2013 Available from: http://www.cdc.gov/nchs/icd/icd9cm.htmAccessed March 27, 2015
   Google Scholar
• BharmalMPayneKAtkinsonMJDesrosiersMPMoriskyDEGemmenEValidation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medicationsHealth Qual Life Outcomes200973619397800
   PubMed Web of Science ®Google Scholar
• SAS Institute IncSAS/STAT^® 92 User’s GuideCary, NC, USASAS Institute Inc2008
   Google Scholar
• CaoZCarterCWilsonKLUstekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasisJ Dermatolog Treat2202014 Epub ahead of print
   Web of Science ®Google Scholar